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Risk of chronic kidney disease in young
adults with impaired glucose tolerance/
impaired fasting glucose: a retrospective
cohort study using electronic primary care
records
Ferozkhan Jadhakhan1*, Tom Marshall1, Ronan Ryan1 and Paramjit Gill1,2
Abstract
Background: The risk of chronic kidney disease (CKD) is known to be elevated in patients with diabetes mellitus
but the risk of young adults aged 18 to 40 years with impaired glucose tolerance/impaired fasting glucose (IGT/IFG)
developing CKD is not well characterised. Furthermore, progression of IGT/IFG to diabetes and subsequent CKD
development is not well understood.
Methods: A retrospective cohort study was undertaken using The Health Improvement Network (THIN) database, a
large dataset of electronic patient records. THIN database is jointly managed by IMS Health Real World Evidence
Solution (http://www.epic-uk.org/index.html) and In Practice System (InPs). Cases were aged 18 to 40, with a diagnosis
of IGT/IFG and registered at a practice contributing to THIN between 2000 and 2015. The study population consisted of
40,092 patients, including 21,454 (53.5%) female and 18,638 (46.5%) male. The median follow-up was approximately
2 years. The outcome was a diagnosis of CKD determined from either clinical coding or laboratory results. For the
primary analysis the unadjusted and adjusted relative risk of CKD in IGT/IFG was compared to age, sex and practice
matched controls with normoglycaemia. For the secondary analysis we compared the incidence of CKD before to after
a diagnosis of type 2 diabetes (T2DM) in the IGT/IFG study cohort.
Results: The Incidence Rate Ratio (IRR) for CKD for IGT/IFG compared to normoglycaemia was 4.0 [95% confidence
interval (CI), 3.2 to 5.1, P < 0.001]. The adjusted IRR was 2.6 [95% CI, 2.0 to 3.4, P < 0.001]. The unadjusted IRR was 8.8
[95% CI, 7.7 to 10.0, P < 0.001] after IGT/IFG patients had developed T2DM and the adjusted IRR was 6.3 [95% CI, 5.5 to
7.2, P < 0.001].
Conclusion: Our results show that young IGT/IFG subjects are also at higher risk of developing CKD. This risk is
modulated by the degree of baseline renal function and glucose tolerance, being higher in those developing T2DM.
Keywords: Impaired glucose tolerance, Impaired fasting glucose, Chronic kidney disease, The Health Improvement
Network (THIN) database, Type 2 diabetes (T2DM), Read code, Incidence rate ratio (IRR)
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Background
CKD is defined as a gradual loss of kidney function for
more than three months with or without kidney damage
[1]. It is common, progressive, usually asymptomatic [2]
and can co-exist with other conditions [2]. The health bur-
den of CKD is likely to rise because the prevalence of type
2 diabetes (T2DM) has been rapidly increasing worldwide
[3]. Although the risk of CKD in patients with diabetes is
relatively well established, the risk of young adults aged 18
to 40 years with IGT/IFG developing CKD is not well char-
acterised. IGT/IFG is an intermediate state between normal
glucose homeostasis and diabetic hyperglycaemia. Individ-
uals with IGT/IFG have glucose levels higher than normal
but not high enough for a diagnosis of diabetes [4]. In a ten
year prospective study of 241 individuals with IGT, 15% de-
veloped T2DM, 53% reverted to normal glucose tolerance
and 22% remained glucose intolerant [5]. Similarly, a 4 year
prospective study conducted in 128 South African Indians
with IGT at baseline, found that after 4 years, 50.4% pro-
gressed to diabetes, 24.8% persisted with IGT and 24.8
reverted to normoglycaemia [6]. There is some evidence
that the incidence of CKD is elevated in individuals with
IGT/IFG, but this is confined to specific populations [7–9].
Furthermore, the progression of IGT/IFG to T2DM and
subsequent CKD development is not well understood. As
many studies have used a single determination of glycaemic
status at baseline, it is not clear whether the risk of develop-
ing a CKD event is confined to people with IGT/IFG who
progress to overt diabetes or whether the risk is still
increased among people with IGT/IFG even if they never
develop diabetes. To address these considerations, we in-
vestigated the incidence of CKD in patients with IGT/IFG
compared to matched controls with normoglycaemia. This
was followed by a comparison of the incidence of CKD be-
fore and after a diagnosis of T2DM. The comparison was
between the IGT/IFG period and the post T2DM period
for all IGT/IFG patients who were in the study cohort.
Methods
Study design
This was a population based, retrospective, open cohort
study using the electronic health record of patients reg-
istered with a family practice contributing to The Health
Improvement Network (THIN) database.
Data source
THIN contains anonymised electronic patient records
from over 600 UK general practices. As of September
2014 the database, held 13 million patients, of whom 3.6
million were actively registered with a general practice:
more than 85 million person years or approximately 6% of
the UK population [10] (http://www.epic-uk.org/our-data/
statistics.shtml). General practices contributing data to
THIN use Vision patient records computer system which
codes clinical data using the 5-byte Read code clinical
classification [11]. Drug prescriptions issued can be linked
to the British National Formulary [12]. Read code lists
used to define the outcomes and conditions of interest
can be found in Additional file 1. These lists were based
on the Quality and Outcomes Framework (QOF) version
(33.0) 2015 rulesets (http://www.hscic.gov.uk/qofbrv33).
Study cohorts
Individual practices were eligible to contribute patients from
the later of one year after installation of Vision and their
Acceptable Mortality Rate (AMR date) until the date of the
last data collection (maximum February 2015). This ensured
that they were using their records system fully and that the
observation period for each patient was not overestimated
[13]. Individual patients were eligible for inclusion in the
study from the latest of the following four dates: practice
eligibility date, patient registration date plus one year (to en-
sure patients did not have the outcome of interest (CKD)
prior to entry), age 18 years, and the study start date (Janu-
ary 2000). Patients were followed up until the earliest of the
following dates: age 41 years, transfer out of the practice or
death, and their practice’s last collection date.
Cases (IGT/IFG definition)
Cases with an incident diagnosis of IGT/IFG were iden-
tified using the earliest of the following events:
1. A Read coded diagnosis of IGT/IFG or Pre-diabetes
– (Appendix 1)
2. Reported measurements of:
a. HbA1c in the range 42–47 mmol/mol [14, 15]
b. Fasting blood glucose (FPG) in the range 6.1–
6.9 mmol/L [15, 16]
c. Oral Glucose Tolerance Test (OGTT) blood glucose
in the range ≥ 7.8 ≤ 11.1 mmol/L [15, 16]
The date of diagnosis of IGT/IFG became the index
date.
Exclusion criteria
1. Patients with an index date prior to their cohort
entry date
2. Patients with a diagnosis of diabetes (type 1 or type
2) prior to their index date
3. Patient cohort exit date was within 90 days of their
index date
4. Patient diagnosed with diabetes (type 1 or type 2)
within 30 days of their index date
5. Patients with a diagnosis of CKD prior to their index
date
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Matched controls
Eligible IGT/IFG cases were matched to three normogly-
caemic controls (without IGT/IFG or T2DM) on gender,
age (within 2 years), and registration at the same family
practice at the IGT/IFG case index date. Matched con-
trols patients may not necessarily have a blood test to
confirm their glycaemic status, suggesting that their gly-
caemic status may not be known but are generally as-
sumed to be normoglycaemic. The same inclusion and
exclusion criteria were applied to potential matches, ex-
cept that they were required not to have a diagnosis of
IGT/IFG on the index date of the IGT/IFG case.
Follow-up
IGT/IFG cases and matched patients were followed up
until the earliest of the following dates: patient died; left
practice; diagnosed with CKD; diagnosed with T2DM;
last data collection from practice; or they reached the
age of 41. For the secondary analysis IGT/IFG cases
were not censored at T2DM diagnosis.
Outcome (CKD definition)
The outcome of interest was a diagnosis of incident
CKD stage 1–5 identified using the earliest of the follow-
ing events:
1. A clinically coded diagnosis of CKD stage (1–2/3–5)
– (Appendix 1) or
2. A single estimated glomerular filtration rate (eGFR)
of (≥60 ml/min/1.73m2 [CKD stage 1–2]) with
additional evidence of kidney disease which include
the following:
 A single albumin creatinine ratio (ACR) of
(≥3 mg/mmol) [17]
 A single protein creatinine ratio (PCR) of (50 mg/
mmol) [17]
 A single urinary albumin/protein loss of 0.5 g/day
[17]
3. eGFR< 60 ml/min/1.73 m2 (CKD stage 3–5)
Covariates
Covariates (risk modifiers) were selected based on their
biological plausibility and previously published epi-
demiological evidence [18, 19]. These covariates were
age, hypertension, heart failure (HF), atrial fibrillation
(AF), cardiovascular disease (CVD) and exposure to a
non-steroidal anti-inflammatory drug (NSAID). The lat-
ter was defined as a prescription during the year before
the index date. All the other covariates were recorded at
any time before the index date.
Ethics approval
THIN database (data collection process) obtained ethical
approval from the South East Multi-centre Research
Ethics Committee (reference number: 07/H1102/103).
The protocol for this study was reviewed and approved
in June 2014 (study reference: 14–038) by the THIN Sci-
entific Review Committee (SCR).
Statistical analysis
 Descriptive statistics
All statistical analyses were conducted using Stata ver-
sion 13.1 (Stata Corp, College Station Texas, USA). Ap-
propriate descriptive statistics were used to summarise
the covariates and matching characteristics for those ex-
posed and unexposed to IGT/IFG. Categorical variables
were investigated using (Chi-square [x2]) test and con-
tinuous variables were analysed using t-test. Since,
length of follow-up had a highly skewed distribution
Mann-Whitney U test was used to compare groups. For
categorical variable (e.g., ethnicity) and continuous vari-
ables (e.g., BMI) a separate ‘missing’ category was cre-
ated for those with missing data.
 Calculating incidence rate of CKD:
1. IGT/IFG compared to normoglycaemia
Adjusted and unadjusted IRRs for CKD in patients
aged 18 to 40 years for the period January 2000 to Feb-
ruary 2015 was estimated. Poisson regression was used
to adjust for patient level covariates (age, hypertension,
heart failure, atrial fibrillation, cardiovascular disease
and steroid treatment).
2. IGT/IFG period compared to post T2DM period
Adjusted and unadjusted IRRs for CKD in patients
aged 18 to 40 years for the period January 2000 to Feb-
ruary 2015 was estimated. Poisson regression was used
to adjust for patient level covariates.
Results
Characteristics of matched cohort study population
The study population consisted of 10,561 patients with
IGT/IFG cases and 29,531 matched controls (Table 1).
For both cases and controls median age at index date
was 35 years, 54% were female and median follow-up
was approximately 1.7 years. Compared to patients with
normoglycaemia, patients with IGT/IFG were more
likely to be of South Asian ethnicity, from areas of
greater deprivation, and to have a BMI of 30.0 kg/m2 or
higher. Atrial fibrillation, heart failure and cardiovascular
disease, hypertension and prescriptions for non-steroidal
anti-inflammatory drugs were more frequent in IGT/IFG
than normoglycaemic patients. During follow-up 11.9%
of IGT/IFG and 0.4% of the normoglycaemia cohorts
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Table 1 Characteristics of the matched cohort (IGT/IFG compared to normoglycaemia)
IGT/IFG
[N = 10,561 (26%)]
Normoglycaemia
[N = 29,531 (74%)]
P-Value
Age, mean [SD] 33.9 [5.3] 33.8 [5.4] 0.015††
Age, median [IQR] 35 [31, 38] 35 [31, 38]
Female, No. (%) 5659 (53.6) 15,795 (53.5) 0.863†
Years of follow-up, mean [SD] 2.3 [2.1] 2.3 [2.0] 0.684†††
Years of follow-up, median [IQR] 1.68 [0.81, 3.16] 1.67 [0.79, 3.14]
Ethnicity, No. (%)
White 3644 (34.5) 11,305 (38.3) < 0.001†
Black 392 (3.7) 784 (2.7)
Asian 1483 (14.0) 1902 (6.4)
Chinese 32 (0.3) 102 (0.4)
Mixed 63 (0.6) 219 (0.7)
Others 130 (1.2) 333 (1.1)
Unknown 4817 (45.6) 14,886 (50.5)
Deprivation quintile, No. (%)
(least deprived) 1 1509 (14.3) 5229 (17.7) < 0.001†
2 1575 (14.9) 4985 (16.9)
3 2177 (20.6) 6149 (20.8)
4 2463 (23.3) 6319 (21.4)
(most deprived) 5 2232 (21.1) 5020 (17.0)
Unknown 605 (5.7) 1829 (6.2)
CVD at index date, No. (%) 190 (1.8) 274 (0.9) < 0.001†
HF at index date, No. (%) 29 (0.30) 21 (0.07) < 0.001†
AF at index date, No. (%) 17 (0.16) 21 (0.07) 0.010†
Hypertension at index date, No. (%) 1112 (10.5) 548 (1.9) < 0.001†
Prescription of NSAID, No. (%) 200 (1.9) 120 (0.4) < 0.001†
BMI (kg/m2), No. (%)
< 20 332 (3.1) 2191 (7.4) < 0.001††
20–24.9 1542 (14.6) 9452 (32.0)
25–29.9 2420 (22.9) 7028 (23.8)
30–34.9 2104 (19.9) 2868 (9.7)
35–39.9 1585 (15.0) 1071 (3.6)
≥ 40 1575 (15.0) 644 (2.2)
Unknown 1003 (9.5) 6277 (21.2)
BMI (kg/m2), mean [SD] 26.0 [5.7] 32.1 [8.2] < 0.001††
BMI (kg/m2), median [IQR] 31 [26, 37.1] 24.9 [22.1, 28.7]
T2DM during follow-up, No. (%) 1262 (11.9) 124 (0.4) < 0.001†
CKD during follow-up, No. (%) 182 (1.7) 126 (0.4) < 0.001†
Country, No. (%)
England 8516 (80.6) 23,661 (80.0) 0.688†
Northern Ireland 270 (2.6) 791 (2.7)
Scotland 804 (7.6) 2321 (7.9)
Wales 971 (9.2) 2758 (9.3)
Values are numbers (percentages) unless otherwise specified. P-values are from X2 test (†) for proportions or t-test (††) for continuous variables (age,
BMI) and Mann-Whitney U test (†††) for follow-up
Abbreviations: CVD cardiovascular disease, HF heart failure, AF atrial fibrillation, NSAID non-steroidal anti-inflammatory drug, BMI body mass index, IQR
interquartile range
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developed T2DM. In addition 1.7% of IGT/IFG cases
were diagnosed with CKD compared to 0.4% in the
normoglycaemia cohort.
Table 2 provides information about the number of
CKD cases first recoded via Read code and first recorded
via biomedical data in the IGT/IFG cohort.
Incidence rate of CKD in persons aged 18 to 40 years
with IGT/IFG compared to those with normoglycaemia
The unadjusted incidence of CKD per 100,000 person-
years in persons with IGT/IFG was 4 times higher than in-
dividuals with normoglycaemia [IRR: 4.0; 95% CI, 3.2 to 5.1,
P < 0.001]. After adjustment for age, sex, ethnic group,
deprivation quintile, BMI categories, cardiovascular disease,
heart failure, atrial fibrillation, hypertension and steroid use,
incidence was reduced to approximately 3 times higher
[IRR: 2.6; 95% CI, 2.0 to 3.4, P < 0.001] in persons with
IGT/IFG (Table 3). In the adjusted analysis there was an in-
creased incidence of CKD for each additional year of age at
IGT/IFG diagnosis [IRR: 1.1; 95% CI, 1.0 to 1.1, P < 0.001]
and an increased incidence in patients with a diagnosis of
hypertension [IRR: 3.1; 95% CI, 2.3 to 4.2, P < 0.001].
Incidence rate of CKD in persons aged 18 to 40 years
before and after T2DM
The unadjusted incidence of CKD in patients with IGT/
IFG after T2DM diagnosis was approximately 9 times
higher [IRR: 8.8; 95% CI, 7.7 to 10.0, P < 0.001] compared
to patients with IGT/IFG. After adjustment with potential
confounders, the incidence of CKD remained high [IRR:
6.3; 95% CI, 5.5 to 7.2, P < 0.001] in patients who pro-
gressed to T2DM compared to those with IGT/IFG
(Table 4). Of the adjusted covariates there was an increased
incidence of CKD for each additional year of age at T2DM
diagnosis [IRR: 1.3 (95% CI, 1.2 to 1.3, P < 0.001] the inci-
dence of CKD was also increased in patients with a diagno-
sis of hypertension [IRR: 1.6; 95% CI, 1.4 to 1.9, P < 0.001].
Discussion
The objective of this study was to investigate the incidence
of CKD in a retrospective matched cohort analysis using
the THIN database and found that young adults with IGT/
IFG were four times more at risk of developing CKD than
individuals with normoglycaemia. After adjusting for age,
sex, ethnic group, deprivation quintile, BMI categories, car-
diovascular disease, heart failure, atrial fibrillation, hyper-
tension and NSAID, the effect of CKD risk was attenuated
but was still 2.6 times higher in individuals with IGT/IFG
than those with normoglycaemia. Among the modifiable
risk factors, hypertension was consistently linked to higher
incidence of CKD. Individuals progressing from IGT/IFG
to T2DM were approximately nine times more likely to be
diagnosed with CKD following diabetes diagnosis than in-
dividuals with IGT/IFG. After adjustment for potential
confounders, incidence of CKD was attenuated but still
showed a significant association. The incidence was re-
duced to approximately 7 times higher in T2DM than the
IGT/IFG cohort.
Table 2 Cases of CKD first recorded by Read code and first
recorded by biomedical data in the IGT/IFG cohort
CKD results Read code Biomedical data Total
CKD cases recorded 26 156 182
Abbreviation: CKD chronic kidney disease
Table 3 Adjusted incidence rate of CKD in IGT/IFG compared to
normoglycaemia
Predictors IRR 95% (CI) P-Value
IGT/IFG vs normoglycaemia 2.6 (2.0, 3.4) < 0.001
Female 1.1 (0.9, 1.4) 0.425
Age (in years) 1.1 (1.0, 1.1) < 0.001
Ethnicity
White Reference 1.0
Asian 1.2 (0.8, 1.7) 0.389
Black 1.0 (0.6, 1.9) 0.955
Chinese 1.2 (0.2, 8.7) 0.845
Mixed 0.5 (0.1, 3.3) 0.439
Other 1.0 (0.4, 2.8) 0.970
Missing 0.7 (0.5, 0.8) 0.001
BMI (kgs/m2)
< 20 Reference 1.0
20–24.9 1.9 (0.9, 4.5) 0.127
25–29.9 2.5 (1.1, 5.8) 0.029
30–34.9 3.2 (1.4, 7.5) 0.006
35–39.9 2.6 (1.1, 6.2) 0.037
≥ 40 3.2 (1.3, 7.6) 0.010
Missing 1.4 (0.6, 3.5) 0.452
Deprivation quintile
Least deprived 1 Reference 1.0
2 0.8 (0.5, 1.3) 0.394
3 1.1 (0.8, 1.6) 0.571
4 0.9 (0.6, 1.4) 0.756
Most deprived 5 1.3 (0.9, 1.9) 0.123
Missing 1.4 (0.8, 2.3) 0.256
CVD 0.9 (0.4, 2.3) 0.905
HF 0.8 (0.1, 6.2) 0.872
AF 2.9 (0.4, 21.0) 0.285
Hypertension 3.1 (2.3, 4.2) < 0.001
Steroid 1.1 (0.9, 1.5) 0.404
Abbreviations: BMI body mass index, CVD cardiovascular disease, HF heart
failure, AF atrial fibrillation, CI confidence interval
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Strengths and limitations
Strengths
The strengths include the large sample size of the
database (THIN contains medical records of over 12
million patients) which is approximately 6% of the
UK population [10]. Generalisability was ensured by
the fact that the dataset includes similar patients to
those seen in primary care across the UK. This re-
flects the fact that data are collected in a non-
interventional fashion during routine clinical practice.
Internal validity (reducing the effect of confounders)
was ensured by matching patient’s age, sex and gen-
eral practice. Although the study was retrospective,
data were collected prospectively, hence eliminating
recall bias. Ascertainment of exposure and outcome
of interest was carried out by both Read coded diag-
nosis and clinical measurements (e.g. HbA1c, ACR
lab results). Additionally, the completeness of lab re-
sults has significantly improved since it is now dir-
ectly fed into GP electronic patient records instead of
entered manually. Therefore, improving ascertainment
of IGT/IFG and CKD for this study and providing a
reliable estimate of incident CKD in young adults
with IGT/IFG. This occurred during the study period
(2000–2015); earlier years may have had under
reporting.
Limitations
The main limitation relates to the potential misclassifica-
tion of patients with IGT/IFG (i.e. patients are identified
as normoglycaemic when in fact they had IGT/IFG but
were not identified because they had no blood tests).
This would dilute the relationship between IGT/IFG and
CKD because some of the controls have IGT/IFG and
the likely association between IGT/IFG and risk of CKD
may be reduced. Additionally, there is also potential for
misclassification of patients with CKD (i.e. patients Read
coded as CKD but with no laboratory reported evidence
of reduced eGFR and patients with laboratory evidence
of CKD but with no Read code labelling of CKD). How-
ever, for this study both laboratory evidence of reduced
eGFR and Read code were used to identify incident
CKD. There is incomplete data on some important con-
founding variables (e.g., ethnicity, BMI). Additionally,
before automated reporting and recording, lab results
were entered manually and in some cases only abnormal
results may have been entered into the GP system: this
could underestimate the incidence of CKD. There is also
potential for ascertainment bias which may arise when
patients who have frequent laboratory tests may be more
likely to have both IGT/IFG and CKD diagnosed. Fur-
thermore, the incidence and prevalence of recorded
CKD depends on general practitioners (GPs) doing
blood tests. This may underestimate the frequency of
CKD and may also be biased because GPs are more
likely to do blood tests for CKD in patients in whom
they suspect CKD. This includes those with diabetes,
hypertension, certain ethnic groups and those with IGT/
IFG. This is reflected in the number of CKD recorded
via Read code and laboratory measurements.
Comparison with other studies
The results of this study appear to be consistent with
previous studies showing an elevated risk of CKD in
Table 4 Adjusted incidence rate of CKD in T2DM compared to
IGT/IFG
Predictors IRR 95% (CI) P-Value
T2DM vs IGT/IFG 6.3 (5.5, 7.2) < 0.001
Female 1.2 (1.0, 1.4) 0.008
Age (in years) 1.3 (1.2, 1.3) < 0.001
Ethnicity
White Reference 1.0
Asian 0.8 (0.6, 1.0) 0.096
Black 0.8 (0.5, 1.2) 0.279
Chinese 0.6 (0.1, 4.2) 0.601
Mixed 0.9 (0.4, 2.2) 0.856
Other 0.8 (0.5, 1.5) 0.538
Missing 0.8 (0.7, 0.9) 0.001
BMI (kgs/m2)
< 20 Reference 1.0
20–24.9 2.1 (0.8, 5.2) 0.110
25–29.9 2.6 (1.1, 6.4) 0.035
30–34.9 3.2 (1.3, 7.8) 0.010
35–39.9 3.3 (1.3, 8.0) 0.009
≥ 40 2.8 (1.1, 6.7) 0.025
Missing 1.9 (0.7, 4.8) 0.181
Deprivation quintile
Least deprived 1 Reference 1.0
2 0.9 (0.7, 1.1) 0.390
3 1.0 (0.9, 1.2) 0.947
4 0.9 (0.7, 1.1) 0.349
Most deprived 5 0.7 (0.6, 0.9) 0.008
Missing 1.0 (0.7, 1.4) 0.830
CVD 1.3 (0.9, 2.0) 0.231
HF 0.7 (0.2, 2.2) 0.514
AF 2.0 (0.7, 5.4) 0.174
Hypertension 1.6 (1.4, 1.9) < 0.001
Steroid 1.0 (0.8, 1.1) 0.675
Abbreviations: BMI body mass index, CVD cardiovascular disease, HF heart
failure, AF atrial fibrillation, CI confidence interval
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adults with IGT/IFG [8, 20, 21]. Watanabe and col-
leagues [9] in the Niigata Preventive Medicine Study,
examining the risk of CKD in individual components of
metabolic syndrome, found the incidence of IGT/IFG
was approximately twice as high in subjects with IGT/
IFG as those with normoglycaemia. Furthermore, a
retrospective study, using data from the Framingham
Offspring cohort study examined the risk of CKD devel-
opment in non-diabetic patients, found that patients
with IGT/IFG were approximately two times more likely
to develop CKD and those with diabetes were approxi-
mately four times more at risk of CKD [7]. Additionally,
A prospective study, using data from the Italian Associ-
ation of Clinical Diabetologists (Associazione Medici
Diabetologi, AMD) initiative, examined risk factors asso-
ciated with the development of CKD in patients aged
(≥18 years) with type 2 diabetes and without CKD or al-
buminuria at baseline. Patients were followed up be-
tween January 1, 2004 and June 30, 2008. During follow-
up, patients who showed reduced kidney function and
albuminuria were older males with poor glycaemic con-
trol, higher systolic blood pressure, hyperlipidaemia and
on hypertensive and lipid lowering drugs [22]. The risk
factors identified in this study are similar to those identi-
fied in the current study. The Framingham study con-
tained data of 2398 patients aged (≥28 years) and 47%
were male compared to a study population of over
40,000 individuals aged 18 to 40 years in the current
study. The gender distributions were similar in both
studies. The follow-up period in the Yamagata and col-
leagues study was 10 years compared a shorter length of
follow-up for individual patients in the current study
(median 2 years approximately). In their study, Yamagata
and colleagues included 113, 764 individuals aged
(≥40 years) and 33% were male compared to a study
population of over 40,000 individuals aged 18 to 40 years
and 46.4% male in the current study. These studies,
however, did not report separate results in persons aged
18 to 40 years with IGT/IFG and risk of CKD, but rather
results were presented for the population as a whole.
Conclusion
To the best of our knowledge, this study was the
first population based study to address this question
utilising data from a large generalisable cohort of
general practices and their patients from across the
UK. It used contemporary data, to investigate the
incidence of CKD in young adults aged 18 to
40 years with IGT/IFG compared to those with
normoglycaemia. This study provides evidence of an
increased risk of CKD amongst young adults with
IGT/IFG. Analyses revealed that patients progressing
from IGT/IFG to T2DM are at an even higher risk
of developing CKD, providing further opportunity
for individuals with IGT/IFG to consider lifestyle
modification and have regular follow-up check of
their kidney function to detect CKD at an early
stage. Additionally, among the modifiable risk fac-
tors, hypertension was consistently linked to higher
incidence of CKD. The result of this study shows
the sizeable adverse effect of IGT/IFG on the devel-
opment of CKD, and if left undetected may cause
serious long term health issues and should be ad-
dressed at an early stage to reduce the future bur-
den of CKD in patients with IGT/IFG.
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